Search Results - "Shepherd, Patricia"

Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders by Bonifazi, Francesca, de Vivo, Antonio, Rosti, Gianantonio, Guilhot, François, Guilhot, Joëlle, Trabacchi, Elena, Hehlmann, Rüdiger, Hochhaus, Andreas, Shepherd, Patricia C.A., Steegmann, Juan Luis, Kluin-Nelemans, Hanneke C., Thaler, Josef, Simonsson, Bengt, Louwagie, Andries, Reiffers, Josy, Mahon, François Xavier, Montefusco, Enrico, Alimena, Giuliana, Hasford, Joerg, Richards, Sue, Saglio, Giuseppe, Testoni, Nicoletta, Martinelli, Giovanni, Tura, Sante, Baccarani, Michele, for the European Study Group on Interferon in Chronic Myeloid Leukemia

“…Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are…”
Get full text

Let’s talk about it: an exploration of the comparative use of three different digital platforms to gather patient-reported outcome measures by Golden, Anna Hundt, Gabriel, Meghan Hufstader, Russo, Jon, Price, Mark, Ruhmel, Stephen, Nilsson, Ami, Delong, Patricia Shepherd, Jelsma, Jennifer, Carty, Michelle

“…Background Patient-reported outcome (PRO) measures provide valuable evidence in clinical trials; however, poor compliance with PRO measures is a notable and…”
Get full text

Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority by Bumm, Thomas, Müller, Christel, Al-Ali, Haifa-Kathrin, Krohn, Knut, Shepherd, Patricia, Schmidt, Erika, Leiblein, Sabine, Franke, Christina, Hennig, Evelin, Friedrich, Thomas, Krahl, Reiner, Niederwieser, Dietger, Deininger, Michael W.N.

“…Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for…”
Get full text

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia : low levels of minimal residual disease are associated with continuing remission by HOCHHAUS, A, REITER, A, HEHLMANN, R, GOLDMAN, J. M, CROSS, N. C. P, SAUSSELE, S, REICHERT, A, EMIG, M, KAEDA, J, SCHULTHEIS, B, BERGER, U, SHEPHERD, P. C. A, ALLAN, N. C

“…Abstract A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a complete response (CR) to treatment with interferon- (IFN),…”
Get full text

Best Practice Recommendations for Electronic Clinical Outcome Assessment Data Changes by Delong, Patricia Shepherd, Humler, Demian, Haag, Tom, Yeomans, Alan, Andrus, Jonathan, Eremenco, Sonya, Finan, Ashley, Gable, Jonathon, Gilfillan, Derek, Howry, Cindy, Kern, Scottie, Lesniewski, Scott, Simpliciano, Kelly, Staunton, Hannah, Turnbull, Jess, Workman, Christina, Raymond, Stephen

“…Historically, there was a tendency amongst electronic clinical outcome assessment (eCOA) service providers and their sponsor clients to prevent changes to eCOA…”
Get full text

Review: Genetics of Man , by F. Clarke Fraser and James J. Nora by Shepherd, Patricia

Get full text

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia by Huntly, Brian J.P., Reid, Alistair G., Bench, Anthony J., Campbell, Lynda J., Telford, Nick, Shepherd, Patricia, Szer, Jeff, Prince, H. Miles, Turner, Paul, Grace, Colin, Nacheva, Elizabeth P., Green, Anthony R.

“…Chronic myeloid leukemia (CML) is characterized by formation of theBCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between…”
Get full text

Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival by Shepherd, P, Suffolk, R, Halsey, J, Allan, N

“…Two hundred and nineteen cases of Ph+ve CML and 15 Ph-ve, BCR+ve CML cases have been analysed to determine the breakpoint site and its relationship to clinical…”
Get more information

Frequency of Blast Crisis after Achieving Complete Cytogenetic Remission in First Chronic Phase CML Patients Who Recieved Imatinib Therapy within Six Months of Diagnosis by Laurence, Arian, Marin, David, Clark, Richard, Shepherd, Patricia, Mackinnon, Stephen

“…Stem cell transplantation (SCT) remains the only proven curative therapy for chronic myeloid leukemia (CML) but is limited by significant procedure related…”
Get full text

Quantification of Residual Disease in Chronic Myelogenous Leukemia Patients on Interferon-α Therapy by Competitive Polymerase Chain Reaction by Hochhaus, Andreas, Lin, Feng, Reiter, Andreas, Skladny, Heyko, Mason, Philip J., Rhee, Frits van, Shepherd, Patricia C.A., Allan, Norman C., Hehlmann, Rudiger, Goldman, John M., Cross, Nicholas C.P.

“…Interferon-α (IFN-α) induces cytogenetic responses of variable degree in patients with chronic myelogenous leukemia (CML). We sought to establish the…”
Get full text

Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase by BOULTWOOD, J, PENIKET, A, WATKINS, F, SHEPHERD, P, MCGALE, P, RICHARDS, S, FIDLER, C, LITTLEWOOD, T. J, WAINSCOAT, J. S

“…Telomere shortening is associated with disease evolution in chronic myelogenous leukemia (CML). We have examined the relationship between diagnostic telomere…”
Get full text

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups by Kluin-Nelemans, Hanneke C., Buck, Georgina, le Cessie, Saskia, Richards, Sue, Beverloo, H. Berna, Falkenburg, J. H. Frederik, Littlewood, Tim, Muus, Petra, Bareford, David, van der Lelie, Hans, Green, Anthony R., Roozendaal, Klaas J., Milne, Alison E., Chapman, Claire S., Shepherd, Patricia

“…The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown. Retrospective analyses suggest that low doses are as effective as high…”
Get full text

Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase by Boultwood, Jackie, Peniket, Andrew, Watkins, Fiona, Shepherd, Patricia, McGale, Paul, Richards, Susan, Fidler, Carrie, Littlewood, Timothy J., Wainscoat, James S.

“…Telomere shortening is associated with disease evolution in chronic myelogenous leukemia (CML). We have examined the relationship between diagnostic telomere…”
Get full text

Teaching and learning about culture: A European journey by Wimpenny, Peter, Gault, Barry, MacLennan, Vivienne, Boast-Bowen, Lesley, Shepherd, Patricia

“…This paper explores the evolving nature of an understanding of culture through attendance on an Intensive Programme (IP) funded by ERASMUS–SOCRATES. The…”
Get full text

Spontaneous clinical regression in chronic lymphocytic leukaemia by Thomas, Ranjit, Ribeiro, Isabel, Shepherd, Patricia, Johnson, Peter, Cook, Margaret, Lakhani, Anil, Kaczmarski, Richard, Carrington, Patrick, Catovsky, Daniel

“…Chronic lymphocytic leukaemia (CLL) is a B‐cell disorder, which has a median survival of over 10 years from diagnosis for stage A disease. The natural history…”
Get full text

Chromosomal abnormalities in Ph- cells of patients on imatinib by McMullin, Mary F., Humphreys, Mervyn, Byrne, Jenny, Russell, Nigel H., Cuthbert, Robert J., O’Dwyer, Michael E.

Get full text

Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia by Boultwood, Jackie, Fidler, Carrie, Shepherd, Patricia, Watkins, Fiona, Snowball, Joanna, Haynes, Sara, Kusec, Rajko, Gaiger, Alex, Littlewood, Timothy J., Peniket, Andrew J., Wainscoat, James S.

“…We studied telomere length in the peripheral blood leukocyte samples of a large group of patients with chronic myelogenous leukemia (CML) by Southern blot…”
Get full text

Wheeling to success by Shepherd, Patricia

Get full text

Correspondence by SHEPHERD, PATRICIA C.A., CHRISTOPHER, BOND, ALLAN, N.C.

Get full text

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission by Hochhaus, Andreas, Reiter, Andreas, Reichert, Susanne Saußele, Anja, Emig, Michael, Kaeda, Jaspal, Schultheis, Beate, Berger, Ute, Shepherd, Patricia C. A., Allan, Norman C., Hehlmann, Rüdiger, Goldman, John M., Cross, Nicholas C. P.

“…A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a complete response (CR) to treatment with interferon- (IFN), defined as…”
Get full text